Several successful start-up companies are emerging in South Carolina as a result of the research coming out of the Centers of Economic Excellence. Many of the Centers are actively pushing technology into the marketplace—launching new products, creating new businesses, and fueling South Carolina’s economy in the process.
|
FirstString Research, a start-up company from the Regenerative Medicine Center, is developing therapeutics for scar prevention and tissue regeneration. The company’s first commercial product is a topical gel that prevents scars.
To read an article about FirstString, click here. |
|
SemiAlloGen, Inc., a start-up company of the Neurosciences Center, has developed a unique technology for the production of vaccines and therapeutics for cancer and neurological diseases like Alzheimer’s. |
|
ImmunoMod, a start-up company from the Childhood Neurotherapeutics Center, has developed a drug to treat juvenile diabetes. The company has received funding from the U.S. Food and Drug Administration to complete the first human patient trials of the drug, which appears to reverse the destruction of cells caused by the disease. |
|
Palmetto Fuel Cell Technologies is a start-up company of the Renewable Fuel Cells for the Fuel Cell Economy Center. The company creates next-generation fuel cell component technologies for the stationary, portable, and transportation
markets. |
|
Hydrogen Hybrid Mobility is a start-up company of the Hydrogen and Fuel Cell Economy Center. The company has modified the standard battery-powered Segway personal transporter to run on a fuel cell that uses hydrogen stored in a canister. The company is looking for ways to use fuel-cell technology for other small mobile devices like wheelchairs and scooters. |
TETRAMER TECHNOLOGIES, L.L.C. |
Tetramer Technologies, L.L.C. is a start-up company of the Optical Materials Center. The company develops specialty polymeric or oligomeric materials with high-value molecular architecture through close research and development relationships with customers. |
|
Advanced Photonic Crystals is a start-up company of the Optical Materials Center. The company provides solid state crystals of exceptionally high quality for use by the laser, photonics, and optoelectronics industries.
|
|
NextGenEn is a start-up company of the Solid Oxide Fuel Cells Center. The company is engaged in research and development in the areas of materials, mechanics, durability, systems, controls, fabrication and manufacturing of solid oxide fuel cells (SOFCs) and related technologies in order to develop and commercialize SOFC-based products. |
 |
MicroVide is a start-up of the Molecular Proteomics Center. The company was launched to move microdialysis and proteolytic pathways technology forward for clinical application and product development. This technological approach will provide for a real-time, practical way to measure critical biological pathways or drug levels in patients during a surgical procedure or during delivery of drugs that have a low threshold for side-effects and toxicity. |
| MitoHealth, Inc. |
MitoHealth, Inc., is a start-up company of the Cancer Drug Discovery Center. |
| Parallel Permeation Inc. |
Parallel Permeation Inc. is a start-up company of the Polymer Nanocomposites Center.
The company develops test equipment for single-detector measurement of the permeation of gas mixtures as well as of any single gas through membrane materials, especially polymer films. |
| Specialty Custom Fibers |
Specialty Custom Fibers is a start-up company of the Advanced Fiber-Based Materials Center. |
| Sim Tunes, LLC |
Sim Tunes is a start-up company of the Clinical Effectiveness and Patient Safety Center. The company facilitates and licenses programmed clinical scenarios used in simulation classes. |
| SchnellGen, Inc. |
SchnellGen is a start-up company of the Cancer Drug Discovery Center. Its mission is to
develop novel therapeutics for the treatment of acute organ failure and wound healing. |
| Vortex Biotechnology Corporation |
Vortex Biotechnology Corporation is a start-up company of the Cancer Drug Discovery Center. The company focuses on the development of inhibitors of Pim protein kinases, which are key regulators of prostate cancer and certain leukemias. Vortex designs, synthesizes, and evaluates proprietary Pim inhibitors, with the goal of moving an agent into clinical testing for the treatment of cancer. |
